BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PALO ALTO, Calif., March 11, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it will host an investor call on March 14, 2022, at 8:00 AM ET to discuss data from its Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i). The results will be featured at the Muscular Dystrophy Association (MDA) 2022 Annual Meeting, taking place in Nashville, Tennessee on March 13 – 16, 2022.

BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

PALO ALTO and SOLANA BEACH, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced the execution of an asset purchase agreement (the Agreement) for the sale of BridgeBio's NULIBRY™ (Fosdenopterin) for Injection. NULIBRY is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening pediatric genetic disorder. The closing of the asset purchase is subject to customary closing conditions.

BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma's NULIBRY™ (Fosdenopterin)

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates

–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio's financial runway into 2024

BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

Adagio Therapeutics

Allakos Inc

Alnylam Pharmaceuticals

argenx

Bicycle Therapeutics Plc - ADR

BioMarin Pharmaceutical

Denali Therapeutics

Incyte

Intra-Cellular Therapies

Jasper Therapeutics

Mirati Therapeutics

Praxis Precision Medicines

SAGE Therapeutics

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

12 biotech stocks to consider buying now as prospects for the sector brighten this year

BridgeBio Pharma (BBIO) closed the most recent trading day at $9.04, moving +1.01% from the previous trading session.

BridgeBio Pharma (BBIO) Gains But Lags Market: What You Should Know

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study

- If successful, BridgeBio's investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body's hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

Amgen

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study

- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

The company has over 5 data readouts from its diverse pipeline in 2022. The stock is recovering from the drop after the recent amyloidosis data.

Buying BridgeBio Pharma On The Drop After Phase 3 Amyloidosis Failure

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

BridgeBio Pharma (BBIO) Moves 14.6% Higher: Will This Strength Last?

This company's market value plunged by around $8 billion in 2021, leading contrarian investors to suspect a bargain opportunity.

Is BridgeBio Pharma Stock a Buy on the Dip?

BridgeBio Pharma Inc (NASDAQ: BBIO) is trading higher Tuesday as the stock rebounds after falling on Monday.  BridgeBio Pharma shares traded lower Monday after the company announced that its Phase 3 trial to treat symptomatic transthyretin amyloid cardiomyopathy did not achieve its primary endpoint.

Why BridgeBio Pharma Shares Are Rising

BridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend.

BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure

Investors are more than a little disappointed with a phase 3 clinical trial failure.

Why Bridgebio Pharma Stock Is Imploding on Monday

BridgeBio Pharma Inc (NASDAQ: BBIO) is trading significantly lower Monday morning after the company announced that its Phase 3 trial to treat symptomatic transthyretin amyloid cardiomyopathy did not achieve its primary endpoint. The ATTRibute-CM independent data monitoring committee recommends continuing the study based on unblinded data reviews.

Why BridgeBio Pharma Shares Are Plummeting Today

The stock price of BridgeBio Pharma Inc (NASDAQ: BBIO) fell by over 60% pre-market today. This is why it happened.

BridgeBio Pharma Stock (BBIO): Why The Price Substantially Fell Today

BridgeBio Pharma Inc. BBIO, +5.84% said Monday that a Phase 3 study of its acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) failed to meet its primary endpoint at Month 12. The company said the decline observed in both arms of the study was similar to expected functional decline in healthy elderly adults, and were also "substantially less" than declines observed in previous untreated arms reviewed by the company.

BridgeBio's acoramidis fails to meet primary endpoint in Phase 3 ATTRibute-CM study

- ATTRibute-CM did not meet its primary endpoint at Month 12. Mean observed six-minute walk distance (6MWD) decline for the acoramidis and placebo arms were 9 meters and 7 meters, respectively. Both declines are similar to healthy elderly adults and less than prior untreated ATTR-CM cohorts

BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study

BridgeBio has been on my radar for over a year now, but the conditions never aligned to start a position. The recent sell-off in the SMID caps has provided an opportunity to buy at a tolerable valuation for the company's prospects.

BridgeBio Pharma: Timing A Buy In 2022

Adaptimmune Therapeutics

Affimed

Aurinia Pharmaceuticals

Axsome Therapeutics

BioCryst Pharmaceuticals

Beam Therapeutics

Amicus Therapeutics

SPDR S&P Biotech ETF

These eight stocks could rebound nicely over the next year and beyond.

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022

Investors need to pay close attention to BridgeBio (BBIO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in BridgeBio (BBIO) Stock?

- The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs

BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio's Novel GPX4 Inhibitor in Multiple Cancer Tumor Types

BridgeBio Pharma Inc (NASDAQ: BBIO) has executed a definitive credit facility agreement with a syndicate of lenders for up to $750 million in financing. This facility, combined with the Company's existing cash balance of $599.6 million, provides access to over $1.2 billion to advance the Company's pipeline programs.

BridgeBio Pharma Secures Debt Financing Of $750M

News for BridgeBio Pharma Inc Stock (BBIO)